Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA

Deepu Madduri, May Hagiwara, Kejal Parikh, Corey Pelletier, Thomas E. Delea, Arianna Kee, Ajai Chari

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Aim: To estimate treatment patterns and healthcare costs among triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Materials & methods: Eligible patients had ≥1 line of therapy (LOT) each of proteasome inhibitors, immunomodulatory drugs and daratumumab in December 2015-September 2018 and received a new LOT. Results: A total of 154 patients were included with a median follow-up of 6.2 months. Median time from diagnosis to new LOT was 41.0 months. Kaplan-Meier estimate of median time to therapy discontinuation was 4.2 months. Mean per-patient, per-month MM-related costs were USD 35,657. Most frequently observed regimens were lenalidomide or pomalidomide + daratumumab (18.2%), lenalidomide or pomalidomide + proteasome inhibitors (15.6%) and lenalidomide or pomalidomide monotherapy (11.0%). Conclusion: Triple-class exposed RRMM patients receive heterogeneous treatments for a short duration with high healthcare resource utilization and costs.

Original languageEnglish
Pages (from-to)503-515
Number of pages13
JournalFuture Oncology
Volume17
Issue number5
DOIs
StatePublished - Feb 2021

Keywords

  • multiple myeloma
  • outcomes
  • real-world
  • relapsed and refractory
  • treatment patterns
  • triple-class exposed

Fingerprint

Dive into the research topics of 'Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA'. Together they form a unique fingerprint.

Cite this